Loading...

Immunicum

DB:1YG
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1YG
DB
SEK737M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Immunicum AB (publ) develops therapeutic cancer vaccines. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
  • Immunicum has significant price volatility in the past 3 months.
1YG Share Price and Events
7 Day Returns
1.2%
DB:1YG
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-
DB:1YG
-9.2%
DE Biotechs
-6.7%
DE Market
1YG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Immunicum (1YG) 1.2% -2.4% -13.3% - - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • No trading data on 1YG.
  • No trading data on 1YG.
Price Volatility
1YG
Industry
5yr Volatility vs Market

1YG Value

 Is Immunicum undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Immunicum. This is due to cash flow or dividend data being unavailable. The share price is €0.759.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Immunicum's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Immunicum's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1YG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-1.90
OM:IMMU Share Price ** OM (2019-04-18) in SEK SEK7.99
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Immunicum.

DB:1YG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:IMMU Share Price ÷ EPS (both in SEK)

= 7.99 ÷ -1.90

-4.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunicum is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Immunicum is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Immunicum's expected growth come at a high price?
Raw Data
DB:1YG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
27%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Immunicum, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Immunicum's assets?
Raw Data
DB:1YG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK5.65
OM:IMMU Share Price * OM (2019-04-18) in SEK SEK7.99
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:1YG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:IMMU Share Price ÷ Book Value per Share (both in SEK)

= 7.99 ÷ 5.65

1.41x

* Primary Listing of Immunicum.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunicum is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Immunicum's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Immunicum has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1YG Future Performance

 How is Immunicum expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Immunicum expected to grow at an attractive rate?
  • Unable to compare Immunicum's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Immunicum's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Immunicum's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1YG Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1YG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 27%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1YG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1YG Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 0 -60 1
2020-12-31 0 -57 1
2019-12-31 0 -267 1
DB:1YG Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 -105 -98
2018-09-30 -88 -90
2018-06-30 -89 -89
2018-03-31 -94 -88
2017-12-31 -46 -80
2017-09-30 -76 -86
2017-06-30 -75 -77
2017-03-31 -68 -72
2016-12-31 -59 -61
2016-09-30 -51 -48
2016-06-30 -40 -44
2016-03-31 -33 -37

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Immunicum is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Immunicum is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1YG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Immunicum Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1YG Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.65 -0.65 -0.65 1.00
2020-12-31 -0.62 -0.62 -0.62 1.00
2019-12-31 -2.89 -2.89 -2.89 1.00
DB:1YG Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -1.90
2018-09-30 -2.01
2018-06-30 -2.25
2018-03-31 -2.81
2017-12-31 -3.09
2017-09-30 -3.37
2017-06-30 -2.92
2017-03-31 -2.96
2016-12-31 -2.67
2016-09-30 -2.22
2016-06-30 -2.18
2016-03-31 -1.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Immunicum will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Immunicum's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Immunicum has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1YG Past Performance

  How has Immunicum performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Immunicum's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Immunicum does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Immunicum's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Immunicum's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Immunicum's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Immunicum Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1YG Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -97.86 25.61 70.93
2018-09-30 -90.47 82.33 7.70
2018-06-30 -88.61 81.06 7.33
2018-03-31 -88.47 79.93 8.21
2017-12-31 -80.34 22.81 57.81
2017-09-30 -86.32 41.27 44.56
2017-06-30 -76.65 48.35 27.73
2017-03-31 -72.45 57.94 14.02
2016-12-31 -61.42 60.86
2016-09-30 -48.09 47.47
2016-06-30 -43.92 43.34
2016-03-31 -36.71 36.74
2015-12-31 -37.71 37.88
2015-09-30 -37.26 37.87
2015-06-30 -35.61 36.41
2015-03-31 -33.39 33.96
2014-12-31 -27.79 28.32
2014-09-30 -20.56 21.62
2014-06-30 -16.18 17.14
2014-03-31 -13.32 14.13
2013-12-31 -10.29 11.11
2013-09-30 -7.59 7.72
2013-06-30 -6.89 6.95
2013-03-31 0.00 -5.75 4.64
2012-12-31 0.00 -5.36 3.13
2012-09-30 0.00 -4.80 2.37
2012-06-30 0.01 -4.24 1.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Immunicum has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Immunicum has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Immunicum improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Immunicum's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Immunicum has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1YG Health

 How is Immunicum's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Immunicum's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Immunicum is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Immunicum's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Immunicum's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 529.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Immunicum Company Filings, last reported 3 months ago.

DB:1YG Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 406.04 0.85 443.80
2018-09-30 117.91 0.85 133.27
2018-06-30 141.43 0.85 149.97
2018-03-31 160.79 0.85 168.06
2017-12-31 189.56 0.85 128.88
2017-09-30 40.87 0.85 53.11
2017-06-30 62.53 0.85 70.73
2017-03-31 81.75 0.85 93.85
2016-12-31 102.39 0.85 112.43
2016-09-30 127.19 0.85 129.03
2016-06-30 139.18 0.85 129.44
2016-03-31 38.84 0.85 42.94
2015-12-31 45.33 0.85 53.11
2015-09-30 56.81 0.85 61.44
2015-06-30 64.63 0.85 68.17
2015-03-31 72.43 0.85 75.77
2014-12-31 83.05 0.85 87.11
2014-09-30 94.07 0.85 97.77
2014-06-30 100.24 0.85 107.84
2014-03-31 14.01 0.85 16.96
2013-12-31 19.02 0.85 20.20
2013-09-30 24.60 0.85 25.61
2013-06-30 24.60 0.85 25.61
2013-03-31
2012-12-31 6.04 0.85 3.27
2012-09-30 6.04 0.85 3.27
2012-06-30 4.43 0.85 5.75
  • Immunicum's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (4.5% vs 0.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Immunicum has sufficient cash runway for more than 3 years based on current free cash flow.
  • Immunicum has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 33.5% each year.
X
Financial health checks
We assess Immunicum's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Immunicum has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1YG Dividends

 What is Immunicum's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Immunicum dividends. Estimated to be 0% next year.
If you bought €2,000 of Immunicum shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Immunicum's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Immunicum's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1YG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1YG Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Immunicum has not reported any payouts.
  • Unable to verify if Immunicum's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Immunicum's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Immunicum has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Immunicum's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Immunicum's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Immunicum afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Immunicum has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1YG Management

 What is the CEO of Immunicum's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carlos de Sousa
AGE 60
TENURE AS CEO 2.5 years
CEO Bio

Dr. Carlos de Sousa has been Chief Executive Officer of Immunicum AB (publ) since October 1, 2016 and also serves as the President. Dr. de Sousa has more than 25 years of relevant experience in the international pharmaceutical and biotech industries, including senior positions at Nycomed/Takeda. Most Recently, he served as the Chief Business Officer and Senior Vice President of Zealand Pharma A/S since December 1, 2015. Dr. de Sousa served as the Chief Business Officer at BBB Therapeutics BV since 2014. Dr. de Sousa served as Chief Business Officer of Newron Pharmaceuticals S.p.A., from June 1, 2007 to February 2009 and its Member of Management Board until February 2009. Dr. de Sousa is a senior pharmaceutical executive with 19 years’ experience in the industry, largely at Pfizer and Novartis AG, served as Senior Vice President and Global Head of Business Development and Licensing at Schwarz Pharma AG. Prior to joining Schwarz Pharma in 2006, he served as Global Head of Negotiations, Neurosciences, at Novartis AG (Basel, Switzerland), where he served for five years in various executive roles within business development and in marketing. Previously, during his twelve years with Pfizer Inc. (Lisbon, Portugal and New York, USA), Dr. de Sousa served positions in clinical development, business development and licensing, as well as regional operations management. Dr. de Sousa earned his M.D. from Lisbon Medical School, University of Lisbon and his MBA from the Stern School of Business, New York University.

CEO Compensation
  • Insufficient data for Carlos to compare compensation growth.
  • Insufficient data for Carlos to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Immunicum management team in years:

2.8
Average Tenure
57
Average Age
  • The tenure for the Immunicum management team is about average.
Management Team

Per-Olof Gunnesson

TITLE
Advisor Contracts
COMPENSATION
SEK162K
AGE
73
TENURE
3.2 yrs

Carlos de Sousa

TITLE
President & CEO
AGE
60
TENURE
2.5 yrs

Alex Karlsson-Parra

TITLE
Founder & Chief Scientific Officer
AGE
68

Michaela Gertz

TITLE
Chief Financial Officer
TENURE
1.2 yrs

Henrik Elofsson

TITLE
Chief Operating Officer
AGE
36
TENURE
5.8 yrs

Margareth Jorvid

TITLE
Head of Regulatory affairs & QA
AGE
57
TENURE
3.3 yrs

Peter Suenaert

TITLE
Chief Medical Officer
AGE
50
TENURE
2.8 yrs

Sharon Longhurst

TITLE
Head of CMC
AGE
49
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Immunicum board of directors in years:

2.4
Average Tenure
59
Average Age
  • The average tenure for the Immunicum board of directors is less than 3 years, this suggests a new board.
Board of Directors

Michael S. Oredsson

TITLE
Chairman
AGE
58
TENURE
1 yrs

Steven Glazer

TITLE
Director
COMPENSATION
SEK44K
AGE
70
TENURE
2.4 yrs

Kerstin Strinnholm

TITLE
Director
COMPENSATION
SEK31K
AGE
58
TENURE
2.4 yrs

Magnus Nilsson

TITLE
Director
COMPENSATION
SEK73K
AGE
62
TENURE
5.3 yrs

Gunnar Magnus Severus Persson

TITLE
Director
COMPENSATION
SEK69K
AGE
58
TENURE
3.3 yrs

Charlotte Edenius

TITLE
Director
COMPENSATION
SEK38K
AGE
60
TENURE
2.4 yrs

Pawel Kalinski

TITLE
Member of Scientific Advisory Board
TENURE
0.6 yrs

Inge Svane

TITLE
Member of Scientific Advisory Board
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Immunicum insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Mar 19 Buy Carlos de Sousa Individual 06. Mar 19 06. Mar 19 5,878 €0.73 €4,302
13. Dec 18 Buy Peter Suenaert Individual 10. Dec 18 10. Dec 18 3,972 €0.82 €3,268
11. Dec 18 Buy Michaela Gertz Individual 06. Dec 18 06. Dec 18 1,400 €0.82 €1,155
X
Management checks
We assess Immunicum's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Immunicum has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1YG News

Simply Wall St News

1YG Company Info

Description

Immunicum AB (publ) develops therapeutic cancer vaccines. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer, as well as is in a Phase I/II clinical trials to treat liver cancer and gastrointestinal stromal tumors. The company’s products also comprise SUBCUVAX, which is in preclinical trials in combination with the adenovirus vector for the treatment of cancer; and CD70-platform, which is in a preclinical phase study works for adaptive immunotherapy for the treatment of various types of solid tumors. Immunicum AB (publ) has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study. The company is based in Gothenburg, Sweden.

Details
Name: Immunicum AB (publ)
1YG
Exchange: DB
Founded:
SEK70,476,643
92,257,531
Website: http://immunicum.se
Address: Immunicum AB (publ)
Grafiska vägen 2,
Gothenburg,
Västra Götaland County, 412 63,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM IMMU Ordinary Shares OMX Nordic Exchange Stockholm SE SEK 22. Apr 2013
DB 1YG Ordinary Shares Deutsche Boerse AG DE EUR 22. Apr 2013
Number of employees
Current staff
Staff numbers
11
Immunicum employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:53
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/15
Last earnings filing: 2019/04/04
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.